SCA
MYOV

Snowden Capital Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Snowden Capital Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$15K – 2192
2021
Q4 		$15K Buy
+1,000
New +$19.1K ﹤0.01% 1421

Other funds holding MYOV

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Snowden Capital Advisors's MYOV Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2022, closing a stake of 1,000 shares — an estimated $15K sold.

Snowden Capital Advisors first reported a position in MYOV in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 89 funds tracked by Wall St. Rank hold MYOV as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 1,000 Myovant Sciences Ltd. shares in Q1 2022, an estimated $15K.
  • Snowden Capital Advisors first reported a position in Myovant Sciences Ltd. in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Myovant Sciences Ltd. position peaked at $15K in Q4 2021.
  • 89 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.